Embolic Neuroprotection System Reduces Risk Of Cardiac Events, Study Reveals Date: October 22, 2008 Source: Cardiovascular Research Foundation Summary: ...

The cohort averaged age 69.6 and 65.9% were men. About 20% were symptomatic, 43% had diabetes, 10.5% had had a previous carotid endarterectomy, and 35.9% a prior coronary stenting or angioplasty.

Reduce risk of stroke and systemic embolism in non-valvular AF 5mg twice daily; 2.5mg twice daily if patient has any 2 of the following: age ≥80yrs, ≤60kg, or creatinine ≥1.5mg/dL.

The main cause of ischemic strokes, which account for 87 percent of all strokes, is atherosclerosis. These fatty deposits, known as plaque, line blood vessel walls and cause blockages. Atherosclerosis ...

A carotid stenting system was linked to the lowest 1-year stroke rates reported for any prospective, multicenter pivotal trial of carotid artery stenting, researchers reported. As Healio ...

Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity TAVR, a transcatheter procedure ...

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received ...

(RTTNews) - InspireMD, Inc. (NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, announced Friday that the company has received CE Mark approval under the ...

EmStop has completed the ‘Controlled Arterial Protection to Ultimately Remove Embolic Material’ (CAPTURE-1) early feasibility clinical study which assessed the EmStop embolic protection system ...

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the company has received CE ...